<DOC>
	<DOCNO>NCT00420303</DOCNO>
	<brief_summary>To assess efficacy safety Etanercept patient spondylarthropathy refractory heel enthesitis .</brief_summary>
	<brief_title>Study Evaluating Etanercept Treatment Refractory Heel Enthesitis Spondylarthropathy</brief_title>
	<detailed_description />
	<mesh_term>Spondylarthropathies</mesh_term>
	<mesh_term>Tendinopathy</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Inclusion criterion Spondylarthropathy Heel enthesitis refractory standard treatment Between 18 70 year age The patient global assessment disease activity ( measure 100 mm VAS ) must &gt; 40 last 48 hour Exclusion criterion Use &gt; 1 local steroid injection within 2 week screen Prior exposure TNFinhibitor , include etanercept Dose NSAIDs change within two week study drug evaluation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>Refractory Heel Enthesitis Spondylarthropathy</keyword>
	<keyword>Spondylarthropathy</keyword>
	<keyword>Refractory Heel Enthesitis</keyword>
</DOC>